V4Cure SAS is a biotech spin off from CEA, and incubated by Paris Biotech Santé. V4CURE received in 2022 the national ILAB grant for innovation with the Honor Award. Team is composed of pharma and life science professionals. V4Cure specializes in the discovery and therapeutic development of innovative peptides derived from animal venoms for new drugs in the cardio-renal field. Business model: To Develop our innovative drug candidates up to POC in clinical trial phase II and out licensing.